Tandem Diabetes (NASDAQ: TNDM) reported Q4 EPS of ($0.46), $0.19 worse than the analyst estimate of ($0.27). Revenue for the quarter came in at $196.8 million versus the consensus estimate of $203.49 million.

GUIDANCE:

Tandem Diabetes sees FY2024 revenue of $850 million, versus the consensus of $841.8 million.

For the year ending December 31, 2024, the Company is providing its 2024 financial guidance as follows:

Non-GAAP sales are estimated to be approximately $850 million, versus the consensus of $841.8 million for the full year and $175 million in the first quarter, versus the consensus of $186.8 million.

Sales inside the United States of approximately $625 million for the full year and $122 million in the first quarter.
Sales outside the United States of approximately $225 million for the full year and $53 million in the first quarter.

Non-GAAP gross margin is estimated to be approximately 51 percent for the full year and approximately 48 percent in the first quarter.
Adjusted EBITDA margin is estimated to be breakeven as a percent of sales for the full year and approximately negative 15 percent in the first quarter.
Non-cash charges included in cost of goods sold and operating expenses are estimated to be approximately $120 million. This includes:

Approximately $100 million non-cash, stock-based compensation expense.
Approximately $20 million depreciation and amortization expense.

For earnings history and earnings-related data on Tandem Diabetes (TNDM) click here.